NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis

Ultragenyx Pharmaceutical Inc. (RARE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

RARE

$15.92

−$0.10 (−0.62%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RARE with… →

RARE Key Statistics

As of Oct 21, 2026
Trading
Open
$16.02
Previous Close
$16.02
Day's Range
15.79–16.31
52-Week Range
12.73–39.89
Volume
2.82M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.35
Valuation
Market Cap
$1.57B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
70.57
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.19
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.82
Financials (FY)
Revenue (FY)
$673.00M+20.18%
Net Income (FY)
−$575.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
−81.73%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
98.59M
1-Year Return
−53.44%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
4.10M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, RARE closed at $15.92, −53.44% over 1 year.

Ultragenyx Pharmaceutical Inc. (RARE) has a market capitalization of $1.57B.

In fiscal 2025, RARE reported revenue of $673.00M.

RARE Stock Return by Calendar Year

Ultragenyx Pharmaceutical Inc. (RARE) 10-year return: what $10,000 became

1 year
$10,000 $4,656
−53.44%
5 years
$10,000 $2,031
−79.69%
10 years
$10,000 $2,398
−76.02%

If you had invested $10,000 in Ultragenyx Pharmaceutical Inc. (RARE) 10 years ago, at the close on October 21, 2016, it would have been worth $2,398 at the close on October 21, 2026: −76.02% in total, −13.31% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−30.78%
2025−45.33%
2024−12.02%
2023+3.22%
2022−44.90%
2021−39.25%
2020+224.12%
2019−1.77%
2018−6.25%
2017−34.03%
2016 (partial year)+7.59%

As of October 21, 2026.

RARE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$673.00M−$575.00M−85.4%
2024$560.00M−$569.00M−101.6%
2023$434.00M−$607.00M−139.9%
2022$363.33M−$707.42M−194.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$673.00M$564.00M−$535.00M−$575.00M−85.4%
2024$560.00M$483.00M−$536.00M−$569.00M−101.6%
2023$434.00M$389.00M−$569.00M−$607.00M−139.9%
2022$363.33M$335.01M−$648.92M−$707.42M−194.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RARE Valuation vs Biotechnology Median

Median of 608 stocks
MetricRAREBiotechnology medianvs median
P/S ratio2.1913.300.2x the median
Profit margin−81.73%−38.31%43.4 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Ultragenyx Pharmaceutical Inc. (RARE) carries a market capitalisation of $1.57B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 1,371.

The 52-week range on file runs from $12.73 to $39.89. The most recent close on file for RARE is $15.92, dated October 21, 2026. That is −$0.10 (−0.62%) against the previous close. The latest close sits 25.06% above that 52-week low.

Financial Health

In fiscal 2025, Ultragenyx Pharmaceutical Inc. reported revenue of $673.00M. Against the prior fiscal year total of $560.00M, that is a change of +20.18%. The same year closed with a net loss of $575.00M. Profit margin runs at −81.73%. That is 43.4 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −5.82.

Across the 4 fiscal years on file, revenue moves from $363.33M in 2022 to $673.00M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 70.57. The price-to-sales ratio is 2.19. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Beta against the wider market is reported at 0.35. Annualized volatility over the trailing 10 years is 56.93%. Over the trailing twelve months the total return is −53.44%. Across 10 years the annualized return works out at −13.31%.

Growth & Income

The record shows no dividend for RARE.

2026 is still running; the total return is −30.78% year to date. The strongest complete calendar year on file is 2020 at +224.12%; the weakest is 2025 at −45.33%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Ultragenyx Pharmaceutical Inc. (RARE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Ultragenyx Pharmaceutical Inc. RARE $1.57B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Ultragenyx Pharmaceutical Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Visit website →